Electronic Supplementary Material (ESI) for Dalton Transactions. This journal is © The Royal Society of Chemistry 2015

## Supporting Information

## Antitumor Properties of Platinum(IV) Prodrug-Loaded Silk Fibroin Nanoparticles

A. Abel Lozano-Pérez, Ana L. Gil, Sergio Pérez, Natalia Cutillas, Hajo Meyer, Mónica Pedreño, Salvador Aznar-Cervantes, Christoph Janiak, Jose Luis Cenis, and José Ruiz\*

## **Table of Contents**

Figure S1. IR spectra of PtBz, PtBz-SFNs and SFNs.	S2
Figure S2. IR spectra of pure PtBz.	S2
<b>Figure S3.</b> TEM pictures of SFNs and PtBz-SFNs at different magnifications.	S3
<b>Figure S4.</b> SEM pictures of SFNs and PtBz-SFNs at different magnifications.	S4
Figure S5. Light microscope pictures of SFNs and PtBz-SFNs.	S4
<b>Figure S6.</b> XRD of SFNs and PtBz-SFNs.	S5
Figure S7. Raman spectra of SFNs and PtBz-SFNs.	S5
Figure S8. UV-spectra of aqueous solutions of SFNs and PtBz-SFNs.	S5
<b>Figure S9</b> . HPLC-MS study from releasing products from PtBz-SFNS in water.	S6
Figure S10. Cell cycle analysis of MCF-7, MDA-MB-231 and SK-BR-3 human	S7
breast cancer cells after 24 h at 310 K.	
Figure S11. Flow cytometry analysis of A2780 and A2780cisR human ovarian	S8
cancer cells after treatment with PtBz-SFNs as detected by annexin V/PI.	
Figure S12. Flow cytometry analysis of MCF-7, MDA-MB-231 and SK-BR-3	S9
human breast cancer cells after treatment with PtBz-SFNs as detected by annexin	
V/PI.	



Figure S1. IR spectra of PtBz (blue), PtBz-SFNs (red) and SFNs (black).



Figure S2. IR spectra of pure PtBz.



Figure S3. TEM pictures of SFNs (a) and PtBz-SFNs (b) at different magnifications.



Figure S4. SEM pictures of SFNs (a) and PtBz-SFNs (b) at different magnifications.



Figure S5. Light microscope pictures of SFNs (a) and PtBz-SFNs (b) at 630-times magnified.



Figure S6. XRD of SFNs (black) and PtBz-SFNs (red).



Figure S7. Raman spectra of SFNs (black) and PtBz-SFNs (red).



Figure S8. UV-spectra of aqueous solutions of SFNs (black) and PtBz-SFNs (red) (c = 1 mg/mL).



Figure S9. HPLC-MS study from release in water after 10 days from PtBz-SFNs at 37 °C.



**Figure S10**. Cell cycle analysis of MCF-7, MDA-MB-231 and SK-BR-3 human breast cancer cells after 24 h at 310 K. A), C) and E) FL2 histograms for negative controls: cells untreated (MCF-7, MDA-MB-231 and SK-BR-3, respectively); B), D) and F) FL2 histograms for cells exposed to PtBz-SFNs, concentration used was 0.5  $\mu$ M.



**Figure S11.** Flow cytometry analysis of A2780 and A2780cisR human ovarian cancer cells after treatment with PtBz-SFNs as detected by annexin V/PI. Density plots for A) and C) untreated cells (control) and for B) and D) cells treated with 1  $\mu$ M (24 h) PtBz-SFNs.



**Figure S12.** Flow cytometry analysis of MCF-7, MDA-MB-231 and SK-BR-3 human breast cancer cells after treatment with PtBz-SFNs as detected by annexin V/PI. Density plots for A), C) and E) untreated cells (control) and for B), D) and F) cells treated with 1  $\mu$ M (24 h) PtBz-SFNs.